Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.67 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA3 | P07451 | 3/20 | 0.53 |
| ▸ | CA4 | P22748 | 3/20 | 0.53 |
| ▸ | CA6 | P23280 | 3/20 | 0.53 |
| ▸ | CA5A | P35218 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2571093 | 1.00 | AKR1C3 (0.67) | AKR1C3AKR1C2KDM4EHSD17B10CA12 | |
| SCHEMBL17157940 | 0.86 | AKR1C3 (0.50) | AKR1C3AKR1C2KDM4EHSD17B10CA12 | |
| SCHEMBL17157941 | 0.86 | AKR1C3 (0.50) | AKR1C3AKR1C2KDM4EHSD17B10CA12 | |
| SCHEMBL290718 | 0.86 | AKR1C3 (0.62) | AKR1C3AKR1C2KDM4EHSD17B10CA12 | |
| SCHEMBL290719 | 0.86 | AKR1C3 (0.62) | AKR1C3AKR1C2KDM4EHSD17B10CA12 | |
| SCHEMBL407484 | 0.83 | KDM4E (0.58) | AKR1C3AKR1C2KDM4EHSD17B10CA12 | |
| SCHEMBL29389045 | 0.83 | KDM4E (0.58) | AKR1C3AKR1C2KDM4EHSD17B10CA12 | |
| SCHEMBL407485 | 0.83 | KDM4E (0.58) | AKR1C3AKR1C2KDM4EHSD17B10CA12 | |
| SCHEMBL27488322 | 0.81 | AKR1C3 (0.43) | AKR1C3AKR1C2ALDH1A1GAAPTPN1 | |
| Hydrochloric Acid SCHEMBL27954236 | 0.81 | KDM4E (0.56) | AKR1C3AKR1C2KDM4EHSD17B10CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023125845-A1 | HETEROAROMATIC BICYCLIC COMPOUND AND ANTIVIRAL APPLICATION THEREOF | 苏州爱科百发生物医药技术有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-10000454-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170081287-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-03-23 | — | — | US | disclosed |
| US-9499467-B2 | Ortho-fluoro substituted compounds for the treatment of metabolic diseases | CALDAN THERAPEUTICS LIMITED (GB) | 2016-11-22 | — | — | US | disclosed |
| WO-2015176267-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-20140058125-A1 | ORTHO-FLUORO SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET (DK) | 2014-02-27 | — | — | US | disclosed |
| EP-2694465-A1 | ORTHO-FLUORO SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | Syddansk Universitet (DK) | 2014-02-12 | — | — | EP | disclosed |
| EP-2385047-B1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI SA (FR) | 2013-05-29 | — | — | EP | disclosed |
| EP-1910333-B1 | PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI SA (FR) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012136221-A1 | ORTHO-FLUORO SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET (DK) | 2012-10-11 | — | — | WO | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20120129828-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. | 2012-05-24 | — | — | US | disclosed |
| EP-2385047-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI (FR) | 2011-11-09 | — | — | EP | disclosed |
| WO-2009154780-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| EP-1910333-A1 | PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | Sanofi-Aventis (FR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007012421-A1 | PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129828-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | S1PR1, S1PR5, S1PR2 | AKR1C3 609/4885AKR1C2 885/4885KDM4E 2854/4885 |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | MYLK2, MYLK, RHOT2 | AKR1C3 3203/4885AKR1C2 3126/4885KDM4E 2732/4885 |
| US-10000454-B2 | Antidiabetic tricyclic compounds | GPR119, GPR65, GPR52 | AKR1C3 1240/4885AKR1C2 1209/4885KDM4E 3958/4885 |
| US-20170081287-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | AKR1C3 1240/4885AKR1C2 1209/4885KDM4E 3958/4885 |
| US-20140058125-A1 | ORTHO-FLUORO SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | GPR119, GPR65, GPR68 | AKR1C3 744/4885AKR1C2 381/4885KDM4E 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.